| Title | Authors (identified) | Published In | Identifier(s) | Topic | Published Date | Match? |
|---|
| Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials | [1]Manuel Benavides, [2]Eduardo Díaz-Rubio, [3]Alfredo Carrato, [4]Albert Abad, [5]Carmen Guillen Ponce, [6]Pilar Garcia-Alfonso, [7]Silvia Gil, [8]María Teresa Cano, [9]María José Safont, [10]Cristina Gravalos, [11]José Luis Manzano, [12]Antonio Sánchez, [13]Julia Alcaide, [14]Rafael López, [15]Bartomeu Massutí, [16]Javier Sastre, [17]Eva Martínez, [18]Pilar Escudero, [19]Miguel Méndez, [20]Enrique Aranda [Full author list] | ESMO Open [missing] | PubMed: 31803504 [ORCID]
| colorectal cancer [missing]; phase II clinical trial [missing]; metastatic colon cancer [missing] | 2019-12-01 | Miguel Mendez (Q58889414; 6 items)
|
| Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02) | [1]Xabier García-Albéniz, [2]Vicente Alonso, [3]Pilar Escudero, [4]Miguel Méndez, [5]Javier Gallego, [6]Jose Ramon Rodríguez, [7]Antonia Salud, [8]Julen Fernández-Plana, [9]Hermini Manzano, [10]Montserrat Zanui, [11]Ester Falcó, [12]Jaime Feliu, [13]Mireia Gil, [14]Carlos Fernández-Martos, [15]Uriel Bohn, [16]Carmen Alonso, [17]Verónica Calderero, [18]Federico Rojo, [19]Miriam Cuatrecasas, [20]Joan Maurel [Full author list] | Oncologist [missing] | DOI: 10.1634/THEONCOLOGIST.2018-0728 [ORCID]
PubMed: 31235483 [ORCID]
| colorectal cancer [missing]; biomarker [missing] | 2019-06-24 | Miguel Mendez (Q58889414; 6 items)
|
| Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients | [1]Vicente Alonso, [2]Pilar Escudero, [3]Carlos Fernández-Martos, [4]Antonia Salud, [5]Miguel Méndez, [6]Javier Gallego, [7]Jose-R Rodriguez, [8]Marta Martín-Richard, [9]Julen Fernández-Plana, [10]Hermini Manzano, [11]José-Carlos Méndez, [12]Monserrat Zanui, [13]Esther Falcó, [14]Mireia Gil-Raga, [15]Federico Rojo, [16]Miriam Cuatrecasas, [17]Jaime Feliu, [18]Xabier García-Albéniz, [19]Joan Maurel [Full author list] | Neoplasia [missing] | DOI: 10.1016/J.NEO.2018.05.004 [ORCID]
PubMed: 29842993 [ORCID]
| colorectal cancer [missing]; cetuximab [missing]; metastatic colon cancer [missing] | 2018-05-26 | Miguel Mendez (Q58889414; 6 items)
|
| Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer | [1]Jordi Codony-Servat, [2]Miriam Cuatrecasas, [3]Elena Asensio, [4]Carla Montironi, [5]Anna Martínez-Cardús, [6]Mercedes Marín-Aguilera, [7]Carlos Horndler, [8]Eva Martínez-Balibrea, [9]Michele Rubini, [10]Pedro Jares, ..., [18]Jaime Feliu, [19]Jose Carlos Méndez, [20]Miguel Méndez, [21]Javier Gallego, [22]Antonieta Salud, ... [Full author list] | British Journal of Cancer [missing] | DOI: 10.1038/BJC.2017.279 [ORCID]
PubMed: 29123263 [ORCID]
| colorectal cancer [missing] | 2017-11-09 | Miguel Mendez (Q58889414; 6 items)
|
| Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). | [1]Julen Fernandez-Plana, [2]Carlos Pericay, [3]Guillermo Quintero, [4]Vicente Alonso, [5]Antonieta Salud, [6]Miguel Mendez, [7]Mercedes Salgado, [8]Eugeni Saigi, [9]Luis Cirera, [10]ACROSS Study Group [Full author list] | BMC Cancer [missing] | DOI: 10.1186/1471-2407-14-865 [ORCID]
PubMed: 25417182 [ORCID]
| colorectal cancer [missing]; cetuximab [missing]; phase II clinical trial [missing]; metastatic colon cancer [missing] | 2014-11-22 | |
| Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer | [1]José-María Roca, [2]Vicente Alonso, [3]Carles Pericay, [4]Pilar Escudero, [5]Antonieta Salud, [6]Ferrán Losa, [7]Luis-Jesús López, [8]Imma Guasch, [9]Miguel Méndez, [10]Guillermo Quintero-Aldana, [11]Carlos Grande, ... [Full author list] | Chemotherapy [missing] | DOI: 10.1159/000313527 [ORCID]
PubMed: 20407241 [ORCID]
| colorectal cancer [missing]; irinotecan [missing]; cetuximab [missing] | 2010-04-21 | Miguel Mendez (Q58889414; 6 items)
|